Subscribe For Free! Sign up to receive the print magazine six times per year and the e-mail newsletter twice a month. Learn more >
To no one’s great surprise, the California Board of Pharmacy voted March 25 to postpone until 2011 a law requiring that prescription drugs be electronically tracked from the time they leave the manufacturer to the time they reach the pharmacy. First enacted in 2004, the law’s original deadline was January 2007. That deadline was pushed back to January 2009, and now it’s been pushed back again. Included among the reasons for the decision was the concern that implementation might be done poorly.
“It really is about time we got some form of e-pedigree system in place” for drug products, states Bryan Liang, law professor, medical professor, and Vice President of the Partnership for Safe Medicine.
He describes the Partnership for Safe Medicine as “a group of organizations and individuals dedicated to ensuring the safety of the drug supply,” including physician, pharmacist, university, industry, and other professional organizations. The partnership has been heavily involved in advocating for a pedigree system to thwart counterfeiting and diversion, but it wants a workable system.
In the next decade, counterfeit drugs will double, according to Alistair Dand, marketing manager for LGR Emballages, a supplier of folding cartons in France. Currently, one out of every two drugs bought on the internet is a fake. “Counterfeiters are benefiting in developed countries from our desire for lifestyle drugs," said Dand, "and in developing countries from the need for life-saving drugs." Dand offered these remarks February 7, 2008, at Pharmapack in Paris.
Certain types of cancer are becoming "chronic" diseases and call for changes in packaging, according to Dr. Joseph Gligorov, an oncologist in France. He made these remarks February 6, 2008, at Pharmapack in Paris, France, during a session titled, "Cancer Treatment: The Emerging Role of Packaging." While cancer rates are growing around the world, from 10 million cases diagnosed in 2000 to 15 million projected in 2020, many of these are due to the aging population, people who may also suffer from a variety of other ailments. More than 650 drugs to fight cancer are currently in the pipeline.
Providing quality healthcare while holding the line on costs continues to be a priority throughout much of the life sciences industry. Watching expenses is a critical task at Group Health as well, where the company’s Seattle facility handles mail-order prescriptions and serves as a central fill location for its 26 pharmacies located in both Washington and Idaho. Since adding a Maverick Enterprises UPM B/T (Universal Packaging Machine with Bottle and Tote infeed), Group Health has reduced its labor needs, improved efficiency within its confined 7,000 sq’ area, and readied itself to handle growing sales volume. In turn, those benefits help to hold down Group Health member costs.
Pharmaceutical innovation and development represents an important aspect of the Latin American economy, with sales of US$24 billion in 2005, up 18.5-percent from 2004. Mexico, Brazil and Argentina are three largest markets in the region, and were responsible for more than 80-percent of the region’s sales in 2005. That’s according to InfoAmericas, a conductor of research and business intelligence across Latin America and the Caribbean. In 2005, the combined annual growth rate of the top seven markets in the region reached 7-percent.
